
Researchers from Loyola University Chicago Stritch School of Medicine in Maywood, Ill have reported a technique that potentially could restore functions to patients weeks or even months after a stroke.
The technique involves jumpstarting the growth of nerve fibres to compensate for brain cells destroyed by the stroke.
Advertisement
It is necessary that a stroke patient get treatment within approximately the first three hours of symptoms. Jumpstarting the growth of nerve fibres to compensate for brain cells destroyed by the stroke can help reverse stroke damage.
The new technique developed by Kartje and colleagues is called anti-nogo-A immunotherapy. It has dramatically improved functions in lab animals that have experienced strokes.
"In the best-case scenario, this would open up the window of time that people could recover and go back to normal functional status," said Gwendolyn Kartje, MD, Ph.D., a professor in the department of cell biology, neurobiology and anatomy and department of neurology at Loyola University Chicago Stritch School of Medicine in Maywood, Ill. and chief of neuroscience research at Edward Hines Jr. VA Hospital in Hines, Ill.
Nogo-A is a protein that inhibits the growth of nerve fibres called axons. It serves as a check on runaway nerve growth that could cause a patient to be overly sensitive to pain, or experience involuntary movements. In anti nogo immunotherapy, an antibody disables the nogo protein.
The left side of the brain controls movements on the right side of the body, and vice versa. Thus, a stroke on the left side of the brain can cause paralysis on the right side of the body.
In such a patient, anti-nogo is believed to spur the growth of axons from the healthy right side of the brain. These axons would then grow into the right side of the body and restore functions lost by the stroke.
Source: ANI
SRM
Advertisement
"In the best-case scenario, this would open up the window of time that people could recover and go back to normal functional status," said Gwendolyn Kartje, MD, Ph.D., a professor in the department of cell biology, neurobiology and anatomy and department of neurology at Loyola University Chicago Stritch School of Medicine in Maywood, Ill. and chief of neuroscience research at Edward Hines Jr. VA Hospital in Hines, Ill.
Nogo-A is a protein that inhibits the growth of nerve fibres called axons. It serves as a check on runaway nerve growth that could cause a patient to be overly sensitive to pain, or experience involuntary movements. In anti nogo immunotherapy, an antibody disables the nogo protein.
The left side of the brain controls movements on the right side of the body, and vice versa. Thus, a stroke on the left side of the brain can cause paralysis on the right side of the body.
In such a patient, anti-nogo is believed to spur the growth of axons from the healthy right side of the brain. These axons would then grow into the right side of the body and restore functions lost by the stroke.
Source: ANI
SRM
Advertisement
Advertisement
|
Advertisement
Recommended Readings

Latest Tropical Disease News

The viral infection of monkeypox has now spread to five provinces in Indonesia, said authorities.

Mpox, previously recognized as Monkeypox, has existed in human circulation since 2016, preceding the 2022 worldwide health emergency it initiated.

Gut bacteria composition is linked to a higher risk of severe malaria and may aid in developing new approaches to prevent severe malaria and its mortality.

Indonesia's Health Ministry is on high alert due to 14 confirmed monkeypox cases since its first detection on October 13.

The Ministry of Health (MoH) in Cambodia has reported the first Zika virus case in the country since 2016.